Researchers isolated a molecule that may be under-produced in the guts of patients
Researchers at the Weizmann Institute of Science have shown in mice that intestinal microbes, collectively termed the gut microbiome, may affect the course of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. As reported today in Nature,progression of an ALS-like disease was slowed after the mice received certain strains of gut microbes or substances known to be secreted by these microbes. Preliminary results suggest that the findings on the regulatory function of the microbiome may be applicable to human patients with ALS.
“Our long-standing scientific and medical goal is to elucidate the impact of the microbiome on human health and disease, with the brain being a fascinating new frontier,” says Prof. Eran Elinav of the Immunology Department. His team performed the study together with that of Prof. Eran Segal of the Computer Science and Applied Mathematics Department. Segal elaborates: “Given increasing evidence that microbiome affects brain function and disease, we wanted to study its potential role in ALS.” The study was led by postdoctoral fellows Drs. Eran Blacher and Stavros Bashiardes, and by staff scientist Dr. Hagit Shapiro, all in the Elinav lab. They collaborated with Dr. Daphna Rothschild, a postdoctoral fellow in Eran Segal’s lab, and Dr. Marc Gotkine, Head of the Motor Neuron Disease Clinic at Hadassah Medical Center, as well as with other scientists from Weizmann and elsewhere.
The scientists started out demonstrating in a series of experiments that the symptoms of an ALS-like disease in transgenic mice worsened after these mice were given broad-spectrum antibiotics to wipe out a substantial portion of their microbiome. In addition, the scientists found that growing these ALS-prone mice in germ-free conditions (in which, by definition, mice carry no microbiome of their own), is exceedingly difficult, as these mice had a hard time surviving in the sterile environment. Together, these results hinted at a potential link between alterations in the microbiome and accelerated disease progression in mice that were genetically susceptible to ALS.
Next, using advanced computational methods, the scientists characterized the composition and function of the microbiome in the ALS-prone mice, comparing them to regular mice. They identified 11 microbial strains that became altered in ALS-prone mice as the disease progressed or even before the mice developed overt ALS symptoms. When the scientists isolated these microbial strains and gave them one by one – in the form of probiotic-like supplements – to ALS-prone mice following antibiotic treatment, some of these strains had a clear negative impact on the ALS-like disease. But one strain, Akkermansia muciniphila, significantly slowed disease progression in the mice and prolonged their survival.
To reveal the mechanism by which Akkermansia may be producing its effect, the scientists examined thousands of small molecules secreted by the gut microbes. They zeroed in on one molecule called nicotinamide (NAM): Its levels in the blood and in the cerebrospinal fluid of ALS-prone mice were reduced following antibiotic treatment and increased after these mice were supplemented with Akkermansia, which was able to secrete this molecule. To confirm that NAM was indeed a microbiome-secreted molecule that could hinder the course of ALS, the scientists continuously infused the ALS-prone mice with NAM. The clinical condition of these mice improved significantly. A detailed study of gene expression in their brains suggested that NAM improved the functioning of their motor neurons.
One strain significantly slowed disease progression in the mice and prolonged their survival
Finally, the researchers examined the microbiome and metabolite profiles of 37 human ALS patients and compared them to those of family members sharing the same household. A detailed genomic analysis suggested that the gut microbiomes of ALS patients were distinct in composition and functional features from those of healthy controls. In particular, numerous microbial genes involved in the synthesis of NAM were significantly suppressed in ALS patients. An analysis of thousands of small molecules in the blood also revealed a distinct pattern in ALS patients as compared to controls. Here too, many of the intermediary molecules involved in the NAM synthesis were altered in the blood of ALS patients. When the researchers tested the levels of NAM itself, they found these to be significantly reduced in both the blood and the brain of 60 human ALS patients as compared to controls. Moreover, there was a correlation between reduced NAM levels and the degree of muscle weakness in the patients.
“These findings are only a first step towards achieving a comprehensive understanding of the potential impact of the microbiome on ALS,” Elinav says, “but they suggest that in the future, various means of altering the microbiome may be harnessed for developing new therapeutic options for ALS.”
Learn more: Gut Microbes May Affect the Course of ALS
The Latest on: Amyotrophic lateral sclerosis
via Google News
The Latest on: Amyotrophic lateral sclerosis
- Jennifer Doudna’s New Gene Editing Company Launches With A $20 Million Round To Develop Genetic Medicineson October 6, 2020 at 7:14 am
What if you had a tool to change the genetic instructions that cause disease? That's what San Francisco-based Scribe Therapeutics hopes to do with its next-generation platform for gene editing.
- Northeast physical therapist assistant students raise $1,800 for ALSon October 6, 2020 at 7:14 am
The fight to raise awareness and find a cure for the progressive nervous system disease amyotrophic lateral sclerosis, or ALS, is still continuing nearly 80 years after baseball player Lou ...
- Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Needon October 5, 2020 at 4:00 am
Advancing Phase 2 and Phase 3 studies of the company's targeted C3 therapy in C3G / IC-MPGN, rare kidney diseases with no approved medicines. First patient in Phase 2 ...
- Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ...on October 5, 2020 at 4:00 am
(GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has initiated registrational programs ...
- Mitsubishi Tanabe Pharma America Announces Presentations At Northeast Amyotrophic Lateral Sclerosis 19th Annual Meetingon September 30, 2020 at 6:00 am
PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four presentations on amyotrophic lateral sclerosis (ALS) will be shared as ...
- Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2029on September 28, 2020 at 10:53 am
Reportlinker.com announces the release of the report "Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2029" - ALS is often called Lou Gehrig’s disease, after the baseball player who was ...
- Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2029on September 28, 2020 at 5:00 am
(UMN) and lower motor neurons (LMN).It is a progressive disease, with patients becoming increasingly dependent on carers and physicians as time from onset increases, and ultimately, it is fatal. ALS ...
- Global Amyotrophic Lateral Sclerosis Treatment Market To Show Startling Growth During Forecast Period 2020–2026 - Zion Market Researchon September 25, 2020 at 4:59 am
Zion Market Research Reports added Latest Research Report titled Global Amyotrophic Lateral Sclerosis Treatment Market To Show Startling Growth During Forecast Period 2020 2026 Zion Market Research to ...
- Amyotrophic lateral sclerosis (ALS)on September 20, 2020 at 9:45 pm
Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease, is a progressive, fatal neurological disease affecting a number of people in South Africa each year. The disorder belongs to ...
- Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosison September 16, 2020 at 9:12 pm
The primary outcome was the rate of decline in the total score on the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R; range, 0 to 48, with higher scores indicating ...
via Bing News